AdvanCell Closes A$18M Series B Funding Led by Morningside
AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.
Andrew Adamovich, CEO and Founder of AdvanCell noted, “We are very pleased with our progress to date and delighted that we will continue our rapid growth with the support of our shareholders. We have had a long-term relationship with our lead investor, Morningside, and are excited to come closer still to our goal to 'Change the Course of Cancer Treatment.'”
Targeted Alpha Therapies represent the most exciting opportunity to treat currently untreatable cancers. The technology harnesses the natural decay and radiochemical properties of certain elements, in combination with specific targeting molecules, to selectively deliver cell-killing radiation to the tumour cell. AdvanCell believes this precise and powerful treatment will rapidly become a leading pillar of cancer treatment, providing treatments for diseases for which there are currently no effective options. Targeted Alpha Therapies demonstrate incredible efficacy, however widespread adoption and large commercial product launches require a scalable and reliable global isotope supply. AdvanCell was established to solve this problem.
AdvanCell’s ability to produce isotope on-demand and at scale, and its in-house radiopharmaceutical manufacturing expertise positions AdvanCell to play a leading role in this rapidly growing market. With additional support from NSW Health Medical Devices Fund and the Federal government’s Research & Development Tax Incentive, AdvanCell has developed a world-first scalable manufacturing platform to produce alpha-emitting isotopes for research, pre-clinical and clinical use and to advance its own and its partners' radiopharmaceutical products.
Anthony Aiudi from Morningside commented, “AdvanCell is leveraging its ability to make alpha isotopes at scale and in clinically useful amounts along with its radiochemistry expertise, to develop an exciting portfolio of Targeted Alpha Therapies. Targeted Alpha Therapies hold incredible promise however their development has been hamstrung by a lack of radioisotope supply. Together with the team at AdvanCell, we look forward to writing a new chapter in oncology, to target large patient populations with significant unmet needs.”
Mr Aiudi has been appointed to the Board of AdvanCell, joining Mr Adamovich, Bill Ferris AC, co-founder of CPE Capital, Adrian “Adi” Patterson, former Australian Nuclear Science and Technology Organisation (ANSTO) CEO and Kevin Cameron, CEO of Ionetix.
Bill Ferris AC, Chair remarked, “Our executive team has articulated a credible pre-clinical and clinical pathway for the delivery of the Company’s novel Targeted Alpha Therapies. Having successfully developed the manufacturing platform essential for the reliable and scalable supply of isotopes, the Company is on schedule with its pre-clinical work and is now moving into first-in-human trials. AdvanCell is on track to become a leading radiopharmaceutical company with a platform technology enabling novel cancer treatments.”
About AdvanCell
AdvanCell is a radiopharmaceutical company developing next-generation cancer treatment. AdvanCell’s Targeted Alpha Therapies are powered by a platform technology – a world-first alpha isotope generator that addresses the greatest unmet need in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell has a world-class team and is honoured to be advised by an outstanding Board of Directors and Scientific Advisory Board. For more information visit www.advancell.com.au
About Morningside
Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai and London, the firm invests globally. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. Morningside partners with academic founders and entrepreneurs to build world-class companies that want to markedly improve the current state of medicine today and ultimately, the lives of patients. In addition to its investment activities, Morningside Ventures is strongly committed to social responsibility. For more information visit www.morningside.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005846/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Allied Telesis Launches SwitchBlade® x908 Generation 3 to Solve Enterprise and Data Center Scalability Challenges17.9.2025 12:40:00 EEST | Press release
Enterprises and data centers face mounting challenges in scaling their networks to support AI, video, IoT, and virtualized workloads. Bandwidth demand is rising, yet many organizations are held back by legacy switches, fragmented operations, and the high cost of oversized chassis systems. To address these issues, Allied Telesis today announced the SwitchBlade x908 Generation 3 (SBx908 GEN3), a next-generation modular switch that combines high-density performance, flexible interface modularity, and future-proof scalability in a compact 3U form factor. Customers can expand capacity on demand with a wide range of interface modules, tailoring the platform to their evolving requirements. Why SBx908 GEN3? The SBx908 GEN3 was developed in direct response to customer demand for scalable, space-efficient networking. Its capacity-on-demand model allows customers to start with only the ports they need and expand seamlessly as traffic grows—avoiding large upfront investments. Unlike traditional sy
LTIMindtree Partners with Shopify to Launch an AI Commerce Center of Excellence17.9.2025 12:30:00 EEST | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced a partnership with Shopify, an AI powered commerce platform for enterprises that empowers businesses to launch, manage, and grow their online stores. Leveraging the Shopify platform, LTIMindtree will set up an AI enabled Center of Excellence (CoE) for Digital Commerce that will help global enterprises to transform at the speed of AI and innovate at scale. LTIMindtree Interactive, the AI-led agency unit of LTIMindtree, is driving the next wave of enterprise digital commerce transformation for CMOs across the globe. Shopify, trusted by millions of merchants, provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. Leveraging the Shopify platform, LTIMindtree will power an AI-driven Centre of Excellence to develop a best-in-class CoE that will: Build advanced AI commerce capabilities to help
Alpha’s latest report explores the impact of retail investors on fund finance provision17.9.2025 12:00:00 EEST | Press release
Alpha Group International plc (LON:ALPH) today announced the launch of its latest Lender Book Report, exploring and analysing the latest fund finance market trends. What does retail investment mean for subscription lines? Private capital funds, once the reserve of institutions such as pension funds and sovereign wealth funds, are rapidly opening up to a wider base of potential investors. Indeed, last month saw President Trump issue an executive order calling for expanded access to private equity and other alternative investments for 401(k) plans and their participants. While the push to open up private capital markets will undoubtedly see an influx of capital coming from new investor types, it also throws up a whole host of ramifications that need to be addressed. One of which is the impact on fund financing, namely subscription line loans. Traditionally, these facilities are secured against capital commitments from institutional investors into an alternative asset manager’s closed-end
LatticeFlow AI Sets a New Standard for AI Governance With Evidence-Based Technical Assessments17.9.2025 11:51:00 EEST | Press release
LatticeFlow AI, the Swiss deep-tech company advancing trustworthy and compliant AI, today announced the Early Access Program for AI GO!, the first platform that enables AI Governance Operations through deep technical assessments. With this, LatticeFlow AI sets a new standard for AI governance and compliance, enabling organizations to accelerate their AI advantage. Traditional Governance, Risk and Compliance (GRC) systems, based on checklists, are insufficient to govern complex and rapidly evolving AI systems. LatticeFlow AI GO! provides rigorous, evidence-based assessments that uncover AI risks, generate audit-ready insights, and empower confident decision-making. The platform equips AI risk and compliance teams with the visibility and confidence they need to harness the full potential of GenAI applications, chatbots, and the latest LLMs. “The only way AI governance can work and scale is when it’s grounded in technical evidence,” said Petar Tsankov, CEO and Co-Founder of LatticeFlow AI
Seven2 and HRK LUNIS Announce Successful Double Closing17.9.2025 11:01:00 EEST | Press release
Seven2, a leading European private equity firm, and HRK LUNIS, one of the leading independent wealth managers in Germany, have successfully completed both the majority stake acquisition of HRK LUNIS by Seven2, announced in March of this year, and the merger with Grossbötzl, Schmitz & Partner, announced in April. The smooth approval process is a positive sign for the German wealth management market and underlines the stability of the sector. With the completed double closing, HRK LUNIS's client assets under management have increased to approximately €7.5 billion and the number of employees to 120. The acquisition of HRK LUNIS is Seven2’s first investment in Germany, marking a key strategic milestone to further expand the private equity firm's position in Europe. Together with Seven2, HRK LUNIS will continue its growth trajectory, further develop its product offering, and optimize its digital capabilities to drive maximum customer benefits. The company offers a broad and competitive rang
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom